Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04753372
Other study ID # Dutch Rivaroxaban CCS Registry
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 21, 2020
Est. completion date September 13, 2023

Study information

Verified date September 2023
Source Maatschap Cardiologie Zwolle
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Registry to describe the impact in terms of effectiveness and safety of the combination treatment of rivaroxaban 2.5 mg twice daily with aspirin on clinical outcomes and practices in a real-life Dutch patient population that are at high risk of ischemic events.


Description:

This study is a national multicentre (~15 sites), prospective, single-arm, observational study in patients treated with rivaroxaban 2.5mg bid on top of ASA75-100mg OD (N=1000). Female and male patients with a diagnosis of CCS and/or symptomatic PAD will be enrolled in the (outpatient) clinic after the decision for treatment with rivaroxaban 2.5mg bid, co-administered with acetylsalicylic acid has been made by the treating physician. The primary effectiveness endpoint is a composite of: - Major Adverse Cardiac Events (MACE including stroke, cardiovascular mortality and myocardial infarction) - Clinically driven coronary, peripheral or carotid revascularization - Stent thrombosis at one year The primary safety endpoint is Major Bleeding at one year. These major bleeding complications are analysed according to the International Society on Thrombosis and Haemostasis (ISTH) criteria as a composite of fatal bleeding, symptomatic bleeding into a critical organ (such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome), bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, or leading to transfusion of two or more units of whole blood or red cells. The secondary endpoints will be: - Occurrence (and date) of stroke - Occurrence (and date) of myocardial infarction - Occurrence (and date) of cardiovascular death - Occurrence (and date) of coronary revascularization procedures (PCI, CABG). - Occurrence (and date) of peripheral revascularization procedures. - Occurrence (and date) of carotid revascularization procedures. - Occurrence (and date) of minor bleeding complications (according to ISTH) In addition, all bleeding events including minor bleedings according to ISTH definitions will be reported.


Recruitment information / eligibility

Status Completed
Enrollment 645
Est. completion date September 13, 2023
Est. primary completion date September 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult (=18 years) patient. - Diagnosis of CAD and/or PAD and high risk of ischemic events. - Patients at high risk of ischaemic events include the following: - CAD + PAD - CAD + Recurrent MI (Previous MI followed by second MI) - CAD + diabetes mellitus (all types) - CAD + chronic kidney disease with eGFR 30-59 ml/min/1.73 m2 (CKD-EPI formula) - CAD + heart failure (ejection fraction =30% - 50%) and New York Heart Association (NYHA) class I or II;) - CAD + CHA2DS2VaSc = 3 (for men) or = 4 (for women) - Patients can only be enrolled in the study if the decision to treat with rivaroxaban plus ASA has been made by the treating physician in advance and independent of study inclusion, however within 4 weeks prior to study inclusion. - Treatment according to local marketing authorization, with rivaroxaban 2.5 mg [BID] and 80mg ASA / 100mg Carbasalate calcium. Treatment of rivaroxaban started within 4 weeks prior or 4 weeks after study inclusion. - Patients who are willing to participate in this study (signed informed consent). Exclusion Criteria: - Hypersensitivity/allergy and known contraindication to ASA/Carbasalate calcium or rivaroxaban - Patients with recent major bleeding, active bleeding, or history with: - History of major clinical bleeding or known coagulopathy - History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke - Known severe liver dysfunction - Patients that have received any organ transplant or await any organ transplant - Patient with anemia (Hb < 6.0 mmol/L) - Patient with active malignancy - Patients with ejection fraction < 30% and/or New York Heart Association (NYHA) class III or IV - Patients with eGFR < 30 ml/min/1.73m2 or undergoing dialysis - Patients with liver failure accompanied with coagulopathy ( incl. Child-Pugh B and C) - Patients with concomitant use of other anticoagulants or antiplatelet drugs - Pregnant or lactating female - Patients currently participating in another investigational drug or drug-coated device study

Study Design


Intervention

Drug:
Rivaroxaban 2.5 MG [Xarelto]
rivaroxaban 2.5mg bid on top of ASA for CAD and/or PAD

Locations

Country Name City State
Netherlands OLVG Amsterdam
Netherlands Rijnstate hospital Arnhem
Netherlands Jeroen Bosch hospital Den Bosch
Netherlands Haaglanden Medisch Centrum Den Haag
Netherlands Hagaziekenhuis Den Haag
Netherlands Medisch Spectrum Twente Enschede
Netherlands Zuyderland Medical Center Heerlen
Netherlands Isala Klinieken, location Meppel Meppel
Netherlands St. Antonius hospital Nieuwegein
Netherlands Elisabeth-Tweesteden hospital Tilburg
Netherlands VieCuri Venlo
Netherlands Isala hospital Zwolle

Sponsors (2)

Lead Sponsor Collaborator
Maatschap Cardiologie Zwolle Diagram B.V.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary Outcome Measures The primary efficacy endpoint is a composite of 1) Major Adverse Cardiovascular Events (MACE), which is a composite endpoint of cardiovascular mortality, myocardial infarction and stroke, 2) clinically driven coronary, peripheral or carotid revascularization, and 3) stent thrombosis, that will be reported at 1 year.
The primary safety endpoint is major bleeding according to the International Society on Thrombosis and Haemostatsis (ISTH) criteria that will be reported at 1 year. It is a composite of 1) fatal bleeding, 2) symptomatic bleeding into a critical organ (such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome), 3) bleeding causing a fall in haemoglobin level of 2 g/dL (1.24 mmol/L) or more, or 4) leading to transfusion of two or more units of whole blood or red cells.
one year
Secondary Secondary Outcome Measures The secondary efficacy and safety endpoint is the incidence of individual endpoints, that will be reported at 1 year:
Occurrence (and date) of stroke
Occurrence (and date) of myocardial infarction
Occurrence (and date) of cardiovascular death
Occurrence (and date) of coronary revascularization procedures (PCI, CABG).
Occurrence (and date) of peripheral revascularization procedures.
Occurrence (and date) of carotid revascularization procedures.
Occurrence (and date) of minor bleeding complications (according to ISTH)
one year
See also
  Status Clinical Trial Phase
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT01435031 - EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions N/A
Terminated NCT01443754 - Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease N/A
Completed NCT00783302 - Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care N/A
Completed NCT00543400 - Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE) Phase 2
Completed NCT05516784 - Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile Phase 4
Completed NCT02873052 - MyoVista Measurements in Patients With Atherosclerosis and CAD
Terminated NCT02984891 - Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging
Completed NCT05292144 - Xperience Pro PMCF Study
Completed NCT02554292 - Post Market Surveillance of SeQuent Please Neo With Scoring Balloon
Active, not recruiting NCT06052319 - A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
Completed NCT00265525 - Evaluation of a Web-based Intervention to Promote Physical Activity in Patients With Heart Disease. Phase 3
Completed NCT03570697 - Imaging of Coronary Plaques in Participants Treated With Evolocumab Phase 3
Terminated NCT05508893 - Screening for Coronary Artery Disease USing Primary Evaluation With Coronary CTA in Aviation Medicine (SUSPECT) N/A
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Completed NCT02098772 - Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol Phase 3